Skip to main content

Volume 12 Supplement 2

Proceedings of the Second Workshop of the Regional Study Group on HCV in the Calabria Region (Southern Italy). The virus-host-therapy pathway in HCV disease management: from bench to bedside in the era of Directly Acting Antivirals

Proceedings

Edited by Alfredo Focà, Carlo Torti and Giampiero Carosi

Publication of this supplement was partly supported by an unrestricted grant provided by Roche. The articles were independently prepared by the authors with no input from Roche. Roche were not involved in selecting the articles for the supplement.

Second Workshop of the Regional Study Group on HCV in the Calabria Region (Southern Italy). The virus-host-therapy pathway in HCV disease management: from bench to bedside in the era of Directly Acting Antivirals.

Catanzaro, Italy16 October 2012

  1. Hepatitis C virus (HCV), first recognized as a cause of transfusion-associated acute and chronic hepatitis in 1989, plays a major role as a cause of chronic liver injury, with potential for neoplastic degenera...

    Authors: S Zaltron, A Spinetti, L Biasi, C Baiguera and F Castelli
    Citation: BMC Infectious Diseases 2012 12(Suppl 2):S2
  2. The advent of triple therapy (TT) with first-generation protease inhibitors boceprevir (BOC) and telaprevir (TVR) in addition to pegylated interferon and ribavirin resulted in a significant gain in terms of su...

    Authors: Salvatore Petta and Antonio Craxì
    Citation: BMC Infectious Diseases 2012 12(Suppl 2):S3
  3. The epidemiological status of HCV in Europe, and in particular in Mediterranean countries, is continuously evolving. The genotype distribution is related to improvement of healthcare conditions, expansion of i...

    Authors: MC Liberto, N Marascio, E Zicca and G Matera
    Citation: BMC Infectious Diseases 2012 12(Suppl 2):S4
  4. Hepatitis C virus infection (HCV) is one of the most pressing health emergencies in the world with a global prevalence of about 170 million people chronically infected worldwide. In Europe, Italy has the highe...

    Authors: Massimo Ciccozzi, Alessandra Lo Presti, Anna Rita Ciccaglione, Gianguglielmo Zehender and Marco Ciotti
    Citation: BMC Infectious Diseases 2012 12(Suppl 2):S5
  5. A major goal of modern medicine is the application of personalized therapies, consisting of decisions and practices tailored to the individual patient. Information about genetic variants, either mutant or poly...

    Authors: Stefania Nucara, Benedetto Caroleo, Vincenzo Guadagnino, Nicola Perrotti and Francesco Trapasso
    Citation: BMC Infectious Diseases 2012 12(Suppl 2):S6
  6. A significant improvement in the rate of eradication of Hepatitis C Virus Genotype 1 has been achieved with the addition of Boceprevir and Telaprevir to pegylated interferon and ribavirin. These two drugs are ...

    Authors: Massimo Puoti, Roberto Rossotti, Giovanna Travi, Maurizio Orso and Maria Cristina Moioli
    Citation: BMC Infectious Diseases 2012 12(Suppl 2):S7
  7. The SINERGIE (South Italian Network for Rational Guidelines and International Epidemiology) project is intended to set up a collaborative network comprising virologists, clinicians and public health officials ...

    Authors: C Torti, M Zazzi, L Abenavoli, F Trapasso, F Cesario, D Corigliano, L Cosco, C Costa, RL Curia, M De Rosa, G Foti, C Giraldi, R Leone, MC Liberto, D Lucchino, N Marascio…
    Citation: BMC Infectious Diseases 2012 12(Suppl 2):S9

Annual Journal Metrics

Peer-review Terminology

  • The following summary describes the peer review process for this journal:

    Identity transparency: Single anonymized

    Reviewer interacts with: Editor

    Review information published: Review reports. Reviewer Identities reviewer opt in. Author/reviewer communication

    More information is available here

Sign up for article alerts and news from this journal